Victory Capital Management
EGRX

Victory Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Victory Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,209
Closed -$142K – 2597
2023
Q4 		$142K Sell
27,209
-1,672
-6% -$16.5K ﹤0.01% 2285
2023
Q3 		$455K Buy
28,881
+1
+0% +$18 ﹤0.01% 2016
2023
Q2 		$561K Buy
28,880
+10,308
+56% +$245K ﹤0.01% 1931
2023
Q1 		$527K Sell
18,572
-10,045
-35% -$298K ﹤0.01% 1983
2022
Q4 		$836K Buy
28,617
+3,572
+14% +$114K ﹤0.01% 1822
2022
Q3 		$662K Buy
25,045
+3,910
+19% +$143K ﹤0.01% 1923
2022
Q2 		$939K Sell
21,135
-496
-2% -$22.8K ﹤0.01% 1777
2022
Q1 		$955K Sell
21,631
-3,074
-12% -$148K ﹤0.01% 1838
2021
Q4 		$1.26M Buy
24,705
+5,822
+31% +$302K ﹤0.01% 1732
2021
Q3 		$1.05M Buy
18,883
+9,408
+99% +$463K ﹤0.01% 1840
2021
Q2 		$406K Buy
9,475
+3,259
+52% +$134K ﹤0.01% 2303
2021
Q1 		$259K Buy
+6,216
New +$289K ﹤0.01% 2451
2020
Q4 		– Sell
-6,255
Closed -$266K – 2591
2020
Q3 		$266K Sell
6,255
-400
-6% -$17.5K ﹤0.01% 2197
2020
Q2 		$319K Sell
6,655
-8,797
-57% -$439K ﹤0.01% 2157
2020
Q1 		$710K Buy
15,452
+3,866
+33% +$194K ﹤0.01% 1969
2019
Q4 		$696K Buy
11,586
+4,828
+71% +$288K ﹤0.01% 1865
2019
Q3 		$382K Buy
6,758
+5,033
+292% +$283K ﹤0.01% 1988
2019
Q2 		$96K Sell
1,725
-3,002
-64% -$157K ﹤0.01% 1633
2019
Q1 		$239K Sell
4,727
-104
-2% -$4.63K ﹤0.01% 1523
2018
Q4 		$195K Sell
4,831
-506,519
-99% -$26.1M ﹤0.01% 1554
2018
Q3 		$35.5M Sell
511,350
-155,184
-23% -$11.8M 0.07% 453
2018
Q2 		$50.4M Sell
666,534
-352,149
-35% -$22.2M 0.11% 304
2018
Q1 		$53.7M Sell
1,018,683
-31,484
-3% -$1.83M 0.12% 272
2017
Q4 		$56.1M Buy
1,050,167
+72,217
+7% +$4.02M 0.12% 264
2017
Q3 		$58.3M Buy
977,950
+9,571
+1% +$579K 0.13% 251
2017
Q2 		$76.4M Sell
968,379
-104,335
-10% -$8.53M 0.18% 162
2017
Q1 		$89M Buy
1,072,714
+209,398
+24% +$15.6M 0.21% 130
2016
Q4 		$68.5M Buy
863,316
+173,056
+25% +$12.6M 0.17% 196
2016
Q3 		$48.3M Buy
+690,260
New +$38.2M 0.14% 247

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Victory Capital Management's EGRX Position: Q1 2024 in Review

Victory Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 27,209 shares — an estimated $142K sold.

Victory Capital Management first reported a position in EGRX in Q3 2016 and held it in 29 quarters. The position peaked at $89M in Q1 2017. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

  • Victory Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Victory Capital Management sold 27,209 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $142K.
  • Victory Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 29 quarters.
  • Victory Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $89M in Q1 2017.
  • 91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Victory Capital Management's 13F filing for Q1 2024, filed 3 May 2024.